Panel: Life Beyond GLP-1s: Where Do Obesity Therapies Go Next?

Session details:

If 2026 was the year GLP-1s went oral, 2027 will be about exploring just how deep the obesity pipelines go. From dual and triple agonists to myostatin inhibitors and Roche’s recent push into urocortin-2 analogs, each new approach brings new opportunities and new challenges.